The primary endpoint of the study was
DVT demonstrated by mandatory venography at day 8-10. At that point
45% of the placebo treated and 31% of the tinzaparin treated patients
had DVT. The rates of PE and death were the same. Blood loss and transfusion
requirements were slightly higher in the patients who received tinzaparin,
but the investigators considered these differences as clinically unimportant.
